Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP000649

Drug Information
NameDexrazoxane
SynonymsICRF-187; (S)-(+)-1,2-Bis(3,5-dioxopiperazin-1-yl)propane; CHEMBL1200778; Dextrorazoxane; I14-10061; D03730; 2,6-Piperazinedione, 4,4'-propylenedi-, (+)-; Dexrazoxano; ADR 529; (+)-1,2-Bis(3,5-dioxopiperazin-1-yl)propane; CHEBI:50224; S1222_Selleck; 2,6-Piperazinedione, 4,4'-(1-methyl-1,2-ethanediyl)bis-, hydrochloride, (S)-; ICRF 187; 2,6-Piperazinedione, 4,4'-(1-methyl-1,2-ethanediyl)bis-, (+)- (9CI); 4,4'-(2S)-propane-1,2-diyldipiperazine-2,6-dione; DB00380; Dexrazoxane; Dexrazoxane HCl; Dexrazoxane (TN); Dexrazoxane hydrochloride; Totect (TN); Razoxane, (S)-Isomer; AC1L2G28; Soluble ICRF (L-isosomer); Totect, ICRF-187, Zinecard, Cardioxane, Dexrazoxane Hydrochloride; BRN 5759131; Dexrazoxanum [INN-Latin]; dyzoxane; Desrazoxane; CHEBI:50223; NSC 169780; D07807; 2,6-Piperazinedione,4,4'-(1-methyl-1,2-ethanediyl)bis-, (S)-; NSC169780; 4-[(2S)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione; Cardioxane; Zinecard (TN); 4-[(2S)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione hydrochloride; C11H16N4O4; (+)-(S)-4,4'-Propylenedi-2,6-piperazinedione; Dexrazoxane [USAN:BAN:INN]; UNII-048L81261F; 2,6-Piperazinedione, 4,4'-(1-methyl-1,2-ethanediyl)bis-, (S)-; HSDB 7319; Dexrazoxanum; 2,6-Piperazinedione,4,4'-[(1S)-1-methyl-1,2-ethanediyl]bis-; DB02444; CID71384; Eucardion; CID6918223; CHEMBL1738; Totect; BIDD:GT0068; (+)-1,2-Bis(3,5-dioxo-1-piperazinyl)propane; UNII-5346058Q7S; 2,6-Piperazinedione, 4,4'-(1-methyl-1,2-ethanediyl)bis-, (+)-; ICRF 187 hydrochloride; Dexrazoxane (USAN/INN); LS-111911; AC1OCF6D; I06-1989; TopoTect; AC1Q6LVI; Savene; 24584-09-6; Dexrazoxano [INN-Spanish]; Zinecard; NCI60_001367; 149003-01-0
Trade NameZinecard; Cardioxane
CompanyPfizer Pharmaceuticals
IndicationBreast CancerApproved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C11H16N4O4.ClH/c1-7(15-5-10(18)13-11(19)6-15)2-14-3-8(16)12-9(
17)4-14;/h7H,2-6H2,1H3,(H,12,16,17)(H,13,18,19);1H/t7-;/m0./s1
InChIKeyBIFMNMPSIYHKDN-FJXQXJEOSA-N
Canonical SMILESCC(CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2.Cl    
Isomeric SMILESC[C@@H](CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2.Cl
Therapeutic ClassAntineoplastic Agents
CAS NumberCAS 24584-09-6
FormulaC11H16N4O4
PubChem Compound IDCID 6918223.
PubChem Substance IDSID 12014716.
ChEBI50223;
SuperDrug ATC IDV03AF02
SuperDrug CAS ID024584096;
TargetDNA topoisomerase IIInhibitor[2][3]
Ref 1FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 076068 To Reference
Ref 2Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines. Anticancer Drug Des. 2001 Dec;16(6):305-15. To Reference
Ref 3Improved targeting of brain tumors using dexrazoxane rescue of topoisomerase II combined with supralethal doses of etoposide and teniposide. Clin Cancer Res. 1998 Jun;4(6):1367-73. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543